文献速递淋巴瘤

一种预测性血清 miRNA 特征通过抑制铁死亡调节因子 EGLN1 和 TXNRD1 影响弥漫性大 B 细胞淋巴瘤细胞活力

A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis.
PubMed 文献 · Br J Haematol · 2025-07-20

研究对 33 例弥漫性大 B 细胞淋巴瘤(DLBCL)患者血清行小 RNA 测序,比较 R-CHOP 难治与缓解者的循环 miRNA 表达。三种 miRNA 联合表达提升预测性能并与无进展生存(PFS)相关,其中 miR-421 和 miR-324-5p 在肿瘤组织中亦按治疗反应差异表达。过表达这些 miRNA 可降低生发中心 B 细胞样亚型细胞的增殖、活力及对 R-CHOP 的耐药性,EGLN1 和 TXNRD1 被鉴定为 miRNA 靶点,沉默或抑制这些基因可损害细胞活力并诱导铁死亡。

要点

  • 33 例 DLBCL 患者血清小 RNA 测序比较 R-CHOP 难治与缓解者,鉴定差异表达的循环 miRNA。
  • 三种 miRNA 联合表达提升预测性能并与 PFS 相关,其中 miR-421 和 miR-324-5p 在肿瘤组织中亦按治疗反应差异表达。
  • EGLN1 和 TXNRD1 被鉴定为 miRNA 靶点,沉默或抑制可损害细胞活力并诱导铁死亡。

核心结论

  • 结果支持将两 miRNA 特征及其靶点用于 DLBCL 的新型联合治疗干预。

研究设计与样本

  • 对 33 例 DLBCL 患者血清行小 RNA 测序,比较 R-CHOP 难治与缓解受试者间差异表达的循环 miRNA。

主要发现

  • 所鉴定 miRNA 中三种联合表达提升预测性能并与 PFS 相关。
  • 三种 miRNA 中 miR-421 和 miR-324-5p 在肿瘤组织中亦按治疗反应差异表达。
  • 在生发中心 B 细胞样 COO 亚型中过表达这些 miRNA 可降低细胞增殖、活力及对 R-CHOP 的耐药性。
  • EGLN1 和 TXNRD1 被鉴定为 miRNA 靶点,沉默或抑制这些基因可损害细胞活力并诱导铁死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disorder. Prognostic factors include genomic alterations and cell-of-origin (COO) subtypes, even though they cannot fully predict treatment response. MicroRNAs (miRNAs) deregulated in patient tumours and blood are promising non-invasive biomarkers. Several circulating miRNAs were found to be correlated with progression-free survival (PFS), independently of other prognosticators. However, miRNA signatures, rather than individual miRNAs, represent more reliable biomarkers and a better mirror of the disease. In this study, we identified circulating miRNAs differentially expressed between R-CHOP refractory and responding subjects by small-RNA sequencing on serum from 33 DLBCL patients. Among the identified miRNAs, the combined expression of three of them improved the predictive performance and was correlated with PFS. Two out of three miRNAs, miR-421 and miR-324-5p, were also differentially expressed in tumour tissues based on treatment response. Overexpressing these miRNAs reduced cell proliferation, viability and resistance to R-CHOP in the germinal centre B-like COO subtype. EGLN1 and TXNRD1, regulators of oxygen metabolism and redox homeostasis, were identified as miRNA targets and the silencing or inhibition of these genes impaired cell viability and induced ferroptosis. These results support the application of a two-miRNA signature and its targets for novel combined therapeutic interventions in DLBCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Regazzo G, Vari G, Marchesi F, et al. A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis. Br J Haematol. 2025. PMID: 40685776. doi:10.1111/bjh.70017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。